PLGA from PolySciTech used in the development of oral insulin delivery nanoparticles

 

Insulin is a necessary component for the treatment of diabetes. Due to its fragile nature and poor bioavailability, it is not viable to normally take insulin in conventional oral form such as via tablet or capsule. For this reason, it is necessary to normally take insulin as an injection. Recently, researchers at The University of Queensland (Australia) utilized PLGA from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop a nanoparticle for delivery of insulin through oral route. This research may provide for improved therapies against diabetes. Read more: Pang, Huiwen, Xiangquan Huang, Zhi Ping Xu, Chen Chen, and Felicity Y. Han. "Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes." Drug Discovery Today (2022): 103393. https://www.sciencedirect.com/science/article/pii/S1359644622003865

“Highlights: Oral administration of insulin mimics the endogenous insulin secretion. Strategies for PLGA nanoparticles to overcome different barriers for oral insulin delivery are discussed. Challenges and future perspectives of PLGA nanoparticles for oral insulin delivery are also put forward. Abstract: Currently, the only practical way to treat type 1 and advanced insulin-dependent type 2 diabetes mellitus (T1/2DM) is the frequent subcutaneous injection of insulin, which is significantly different physiologically from endogenous insulin secretion from pancreatic islets and can lead to hyperinsulinemia, pain, and infection in patients with poor compliance. Hence, oral insulin delivery has been actively pursued to revolutionize the treatment of insulin-dependent diabetes. In this review, we provide an overview of recent progress in developing poly(lactic co-glycolic acid) (PLGA) nanoparticles (NPs) for oral insulin delivery. Different strategies for insulin-loaded PLGA NPs to achieve normoglycemic effects are discussed. Finally, challenges and future perspectives of PLGA NPs for oral insulin delivery are put forward. Keywords: oral insulin poly(lactic co-glycolic acid) (PLGA) biological barriers mucus epithelium gastrointestinal tract (GIT)”